Theragun, Inc. v. Tzumi Electronics LLC

District Court, S.D. New York·Decided September 29, 2023·No. 1:21-cv-07803·Unknown

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK THERABODY, INC., Plaintiff, MEMORANDUM OPINION & ORDER - against - 21 Civ. 7803 (PGG) (RWL) TZUMI ELECTRONICS LLC, TZUMIINC., and DOES 1 THROUGH 10, Defendants.

PAUL G. GARDEPHE, U.S.D.J.: Plaintiff Therabody, Inc. brings patent infringement claims against Defendants Tzumi Electronics LLC, Tzumi Inc., and Does | through 10 (collectively, “Tzumi’’). Therabody alleges that Tzumi infringed fourteen utility and design patents relating to percussive massage devices and their attachments. (See Second Amended Complaint (“SAC”) (Dkt. No. 53) J§ 41- 219) . Tzumi has moved for summary judgment of non-infringement as to four Therabody patents, and has moved to dismiss Therabody’s claims of willfulness as to eight of the fourteen Therabody patents at issue. (Dkt. Nos. 67, 84) On November 28, 2022, Judge Lehrburger issued a Report and Recommendation (“R&R”) recommending that Tzumi’s motion for summary judgment be denied. (See Nov. 28, 2022 R&R (Dkt. No. 97)) On December 19, 2022, Judge Lehrburger issued an R&R recommending that Tzumi’s motion to dismiss likewise be denied. (See Dec. 19, 2022 R&R (Dkt. No. 105)) For the reasons stated below, Tzumi’s objections will be overruled, and Judge Lehrburger’s recommendations that Tzumi’s motion for summary judgment and motion to dismiss be denied will be adopted.

BACKGROUND 1, FACTS! A. Factual Background for Motion to Dismiss Therabody “develops, manufactures, and sells ‘innovative percussive therapy devices and attachments.’” (Dec. 19, 2022 R&R (Dkt. No. 105) at 1 (quoting SAC (Dkt. No. 53) 4 11)) “Its patented and patent-pending devices have ‘received industry praise and recognition.”” (Id. (quoting SAC (Dkt. No. 53) ¢33)) Therabody lists its patents on its website. (Id. at 2 (citing SAC (Dkt. No. 53) J§ 56, 71, 86, 97, 108, 119, 130, 141, 153, 167, 178, 189, 204, 219)) “Tzumi competes with Therabody in the percussive massage device industry,” and Therabody alleges that Tzumi has willfully infringed fourteen of Therabody’s patents. (Id. (citing SAC (Dkt. No. 53) 9 34)) On April 21, 2021, before Therabody filed the instant action, it “sent a letter to Tzumi claiming that several of [Tzumi’s] products infringed six of Therabody’s patents, .. . and demanding that Tzumi discontinue its manufacture, sale, use, and importation of the allegedly infringing products.” (Id. (citing SAC (Dkt. No. 53) § 38)) These patents are U.S. Patents 10,945,915; D849,261; D861,182; D890,943; D896,393; and D845,500. (1d. at 2 n.3) According to Therabody, Tzumi did not respond to the letter and continued to sell the accused products. (Id. (citing SAC (Dkt. No. 53) {J 39-40))

Because the parties have not objected to Judge Lehrburger’s factual statement in either R&R, this Court adopts it in full. See Silverman v. 3D Total Solutions, Inc., No. 18 Civ. 10231 (AT), 2020 WL 1285049, at *1 n.1 (S.D.N.Y. Mar. 18, 2020) (“Because the parties have not objected to the R&R’s characterization of the background facts .. . , the Court adopts the R&R’s ‘Background’ section and takes the facts characterized therein as true.”); Hafford v. Aetna Life Ins. Co., No. 16 Civ. 4425 (VEC) (SN), 2017 WL 4083580, at *1 (S.D.N.Y. Sept. 13, 2017) (“The parties do not object to the Magistrate Judge’s . . . recitation of the facts of this case, and the Court adopts them in full.”).

In the September 17, 2021 Complaint, Therabody alleges that Tzumi infringed two additional patents — U.S. Patents 10,702,448 and 10,918,565 — “through [Tzumi’s] manufacture and sale of two percussive massage devices and four attachments.” (Id. (citing Cmplt. (Dkt. No. 1) §§ 26-28)) In the November 23, 2021 Amended Complaint, Therabody alleges that Tzumi infringed four additional patents — U.S. Patents 10,557,490; 11,160,723; D837,636; and D918,404 — “through manufacture and sale of an additional percussive massage device and a connector.” (Id. at 2-3 (citing Am. Cmplt. (Dkt. No. 19) §§ 32-35)) On March 29, 2022, Therabody notified informed Tzumi that it was infringing two additional patents — U.S. Patents 10,857,064 and 11,160,722. (Id. at 3 (citing SAC (Dkt. No. 53) ff 198-99, 204, 213-14, 219)) In the May 9, 2022 SAC, Therabody alleges Tzumi’s infringement of the six patents discussed in the April 21, 2021 letter, the two additional patents alleged in the Complaint, the four additional patents alleged in the Amended Complaint, the two additional patents discussed in the March 29, 2022 email, and “‘an additional infringing device made and sold by Tzumi.” (Id. (citing SAC (Dkt. No. 53) §§ 34-37)) According to Therabody, “Izumi continues to sell the devices accused of infringement in the [SAC].” (Id. (citing SAC (Dkt. No. 53) 4 40)) Therabody claims willful infringement and alleges, as to each patent, that “Defendants’ acts of infringement, including their continued sales of the [infringing [p]roducts after notice of their infringement through Therabody’s April 21, 2021 letter, the service of the original and amended complaints, and Therabody’s marking of its products via its website at https://www.therabody.com/us/en-us/patents.html, have been, and continue to be, willful and deliberate and therefore warrant the award of attorneys’ fees pursuant to 35 U.S. § 285 and the award of enhanced damages pursuant to 35 U.S.C. § 284.” (Id. (quoting SAC (Dkt. No. 53) §§ 56, 71, 86, 97, 108, 119, 130, 141, 153, 167, 178, 189, 204, 219))

Tzumi has moved to dismiss allegations of willful infringement as to the eight patents-in-suit that are not mentioned in the April 21, 2021 letter. These patents are U.S. Patents 10,702,448; 10,918,565; 10,557,490; 11,160,723; D837,636; D918,404; 10,857,064; and 11,160,722. (1d. at 3-4; see also Def. 12(b)(6) Br. (Dkt. No. 85) at 5, 7) B. Factual Background for Summary Judgment Motion Therabody asserts infringement of the independent claims 1 and 6 of U.S. Patent 10,702,448 (“the ’448 Patent’); independent claims 1, 8, 9, 10, 14, 15, and 16 of U.S. Patent 10,918,565 (“the °556 Patent”); independent claims 1 and 16 of U.S. Patent 10,857,064 (‘the Patent’’); and independent claims 1, 6, 11, and 17 of U.S. Patent 11,160,722 (“the ’722 Patent”). (Nov. 28, 2022 R&R (Dkt. No. 97) at 3 (citing Pitf Resp. R. 56.1 Stmt. (Dkt. No. 71) 11) In seeking summary judgment as to these claims, Tzumi contends that each claim contains “grasping limitations” which, under [Tzumi’s] proposed claim construction, require that “all three handles [of the percussive massage device] must be of a length sufficient for a person with a large hand to firmly and comfortably grip each handle portion with at least three to four fingers extending through the opening. (id. (quoting Def. R. 56.1 Stmt. (Dkt. No. 68) § 2; Def. Sum. Jgmt. Br. (Dkt. No. 69) at 4-5, 14)) “Tzumi asserts that because its accused devices . . . cannot be so grasped, they cannot literally infringe the asserted claims.” Moreover, ““Therabody’s statements and amendments during prosecution of the patents estop it from asserting infringement under the doctrine of equivalents.” (id. at 4 (citing Def. Sum. Jgmt. Br. (Dkt. No. 69) at 5)) Judge Lehrburger summarizes Therabody’s patents, their prosecution history, and Tzumi’s accused products as follows:

1, The °448 Patent The °448 Patent — which Therabody applied for on November 6, 2019, and which was issued on July 7, 2020 — “claims a ‘percussive massage device and method of use.’” (Id. at 5 (quoting Def. R. 56.1 Stmt., Ex. 1 (Dkt. No. 68-1) at 15)) As originally filed, claim 1 reads as follows (with the “grasping limitations” printed in bold): 1.

Free access — add to your briefcase to read the full text and ask questions with AI

Theragun, Inc. v. Tzumi Electronics LLC, (S.D.N.Y. 2023).

Theragun, Inc. v. Tzumi Electronics LLC (Theragun, Inc. v. Tzumi Electronics LLC) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Spinelli v. City of New York
579 F.3d 160 (Second Circuit, 2009)
Port Dock & Stone Corp. v. Oldcastle Northeast, Inc.
507 F.3d 117 (Second Circuit, 2007)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Thorner v. Sony Computer Entertainment America LLC
669 F.3d 1362 (Federal Circuit, 2012)
United States v. Fred Snow, Marcus Snow, Rahad Ross
462 F.3d 55 (Second Circuit, 2006)
Guilbert v. Gardner
480 F.3d 140 (Second Circuit, 2007)
Beyer v. County of Nassau
524 F.3d 160 (Second Circuit, 2008)
Hicks v. Baines
593 F.3d 159 (Second Circuit, 2010)